Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 7/20 | 0.54 |
| ▸ | OGFRL1 | Q5TC84 | 4/20 | 0.54 |
| ▸ | OPRL1 | P41146 | 4/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | USP2 | O75604 | 2/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.38 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.38 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2141211 | 0.87 | OPRM1 (0.73) | OPRM1OGFRL1OPRL1OPRD1OPRK1 | |
| SCHEMBL2140032 | 0.86 | OPRM1 (0.54) | OPRM1OGFRL1OPRL1ALDH1A1MEN1 | |
| SCHEMBL2140335 | 0.85 | OPRM1 (0.58) | OPRM1OGFRL1OPRL1ALDH1A1MEN1 | |
| SCHEMBL2141136 | 0.85 | OPRM1 (0.54) | OPRM1OGFRL1OPRL1MEN1KMT2A | |
| SCHEMBL2141647 | 0.85 | OPRM1 (0.54) | OPRM1OGFRL1OPRL1MEN1KMT2A | |
| SCHEMBL2142957 | 0.84 | OPRM1 (0.52) | OPRM1OGFRL1OPRL1MEN1KMT2A | |
| SCHEMBL2137582 | 0.84 | OPRM1 (0.52) | OPRM1OGFRL1OPRL1ALDH1A1MEN1 | |
| SCHEMBL2141092 | 0.84 | OPRM1 (0.52) | OPRM1OGFRL1OPRL1KMT2ACHRM2 | |
| SCHEMBL2138536 | 0.83 | OPRM1 (0.51) | OPRM1OGFRL1OPRL1ALDH1A1 | |
| SCHEMBL2142688 | 0.82 | OPRM1 (0.54) | OPRM1OGFRL1OPRL1ALDH1A1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080221141-A1 | 1 1,1-(3-dimethylamino-3-phenylpentamethylene)-1,3,4,9-tetrahydropyrano[3,4-b]indole; affinity to mu -opioid receptor | GRUENENTHAL GMBH (DE) | 2008-09-11 | — | — | US | claimed |
| US-20160271107-A1 | Spirocyclic Cyclohexane Compounds Useful To Treat Substance Dependency | GRUENENTHAL GMBH (DE) | 2016-09-22 | — | — | US | disclosed |
| US-20160271107-A1 | Spirocyclic Cyclohexane Compounds Useful To Treat Substance Dependency | GRUENENTHAL GMBH (DE) | 2016-09-22 | — | — | US | disclosed |
| US-20140303125-A1 | Spirocyclic Cyclohexane Compounds Useful To Treat Substance Dependency | GRUENENTHAL GMBH (DE) | 2014-10-09 | — | — | US | disclosed |
| US-20140303125-A1 | Spirocyclic Cyclohexane Compounds Useful To Treat Substance Dependency | GRUENENTHAL GMBH (DE) | 2014-10-09 | — | — | US | disclosed |
| EP-1868600-B1 | SPIROCYCLIC CYCLOHEXANE DERIVATIVES FOR USE IN THE TREATMENT OF SUBSTANCE DEPENDENCY | GRUENENTHAL GMBH (DE) | 2012-06-27 | — | — | EP | disclosed |
| EP-1868600-B1 | SPIROCYCLIC CYCLOHEXANE DERIVATIVES FOR USE IN THE TREATMENT OF SUBSTANCE DEPENDENCY | GRUENENTHAL GMBH (DE) | 2012-06-27 | — | — | EP | disclosed |
| US-8034936-B2 | Spirocyclic cyclohexane compounds useful to treat substance dependency | GRUENENTHAL GMBH (DE) | 2011-10-11 | — | — | US | disclosed |
| US-8034936-B2 | Spirocyclic cyclohexane compounds useful to treat substance dependency | GRUENENTHAL GMBH (DE) | 2011-10-11 | — | — | US | disclosed |
| US-20110053970-A1 | Spirocyclic Cyclohexane Compounds Useful To Treat Substance Dependency | GRUENENTHAL GMBH (DE) | 2011-03-03 | — | — | US | disclosed |
| US-20110053970-A1 | Spirocyclic Cyclohexane Compounds Useful To Treat Substance Dependency | GRUENENTHAL GMBH (DE) | 2011-03-03 | — | — | US | disclosed |
| US-20080221141-A1 | 1 1,1-(3-dimethylamino-3-phenylpentamethylene)-1,3,4,9-tetrahydropyrano[3,4-b]indole; affinity to mu -opioid receptor | GRUENENTHAL GMBH (DE) | 2008-09-11 | — | — | US | disclosed |
| US-20080221141-A1 | 1 1,1-(3-dimethylamino-3-phenylpentamethylene)-1,3,4,9-tetrahydropyrano[3,4-b]indole; affinity to mu -opioid receptor | GRUENENTHAL GMBH (DE) | 2008-09-11 | — | — | US | disclosed |
| US-20080221141-A1 | 1 1,1-(3-dimethylamino-3-phenylpentamethylene)-1,3,4,9-tetrahydropyrano[3,4-b]indole; affinity to mu -opioid receptor | GRUENENTHAL GMBH (DE) | 2008-09-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080221141-A1 | 1 1,1-(3-dimethylamino-3-phenylpentamethylene)-1,3,4,9-tetrahydropyrano[3,4-b]indole; affinity to mu -opioid receptor | OPRM1, OPRK1, OPRD1 | OPRM1 1/4885OGFRL1 34/4885OPRL1 4/4885 |
| US-20110053970-A1 | Spirocyclic Cyclohexane Compounds Useful To Treat Substance Dependency | TACR2, OPRK1, OPRD1 | OPRM1 8/4885OGFRL1 307/4885OPRL1 12/4885 |
| US-20140303125-A1 | Spirocyclic Cyclohexane Compounds Useful To Treat Substance Dependency | TACR2, OPRK1, OPRD1 | OPRM1 8/4885OGFRL1 307/4885OPRL1 12/4885 |
| US-20160271107-A1 | Spirocyclic Cyclohexane Compounds Useful To Treat Substance Dependency | TACR2, OPRK1, OPRD1 | OPRM1 8/4885OGFRL1 307/4885OPRL1 12/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.